Selected research
Industry Research
Vigabatrin Industry Research Report 2026
Market perspective
The global Vigabatrin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Vigabatrin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Vigabatrin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Vigabatrin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Vigabatrin include Sanofi, Novartis, Upsher-Smith, Perrigo, Lundbeck, Grindeks, Endo International, Dr. Fisher Farma and Cipla, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Vigabatrin market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Vigabatrin Market by Company
Sanofi
Novartis
Upsher-Smith
Perrigo
Lundbeck
Grindeks
Endo International
Dr. Fisher Farma
Cipla
Benta Pharma Industries
Amneal Pharma
Vigabatrin Segment by Type
Tablet
Powder
Vigabatrin Segment by Application
Partial-Onset Seizures
Refractory Complex Partial Seizures
Infantile Spasms (IS)
Vigabatrin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vigabatrin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vigabatrin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vigabatrin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Vigabatrin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Vigabatrin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Vigabatrin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablet
- Powder
Applications
- Partial-Onset Seizures
- Refractory Complex Partial Seizures
- Infantile Spasms (IS)
Companies covered
- Sanofi
- Novartis
- Upsher-Smith
- Perrigo
- Lundbeck
- Grindeks
- Endo International
- Dr. Fisher Farma
- Cipla
- Benta Pharma Industries
- Amneal Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Vigabatrin Market Size (2021-2032)
- 2.2.2 Global Vigabatrin Sales (2021-2032)
- 2.2.3 Global Vigabatrin Market Average Price (2021-2032)
- 2.3 Vigabatrin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tablet
- 2.3.3 Powder
- 2.4 Vigabatrin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Partial-Onset Seizures
- 2.4.3 Refractory Complex Partial Seizures
- 2.4.4 Infantile Spasms (IS)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Vigabatrin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Vigabatrin Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Vigabatrin Revenue of Manufacturers (2021-2026)
- 3.4 Global Vigabatrin Average Price by Manufacturers (2021-2026)
- 3.5 Global Vigabatrin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Vigabatrin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Vigabatrin, Product Type & Application
- 3.8 Global Manufacturers of Vigabatrin, Established Date
- 3.9 Global Vigabatrin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Vigabatrin Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Vigabatrin Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Upsher-Smith
- 4.3.1 Upsher-Smith Company Information
- 4.3.2 Upsher-Smith Business Overview
- 4.3.3 Upsher-Smith Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Upsher-Smith Vigabatrin Product Portfolio
- 4.3.5 Upsher-Smith Recent Developments
- 4.4 Perrigo
- 4.4.1 Perrigo Company Information
- 4.4.2 Perrigo Business Overview
- 4.4.3 Perrigo Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Perrigo Vigabatrin Product Portfolio
- 4.4.5 Perrigo Recent Developments
- 4.5 Lundbeck
- 4.5.1 Lundbeck Company Information
- 4.5.2 Lundbeck Business Overview
- 4.5.3 Lundbeck Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Lundbeck Vigabatrin Product Portfolio
- 4.5.5 Lundbeck Recent Developments
- 4.6 Grindeks
- 4.6.1 Grindeks Company Information
- 4.6.2 Grindeks Business Overview
- 4.6.3 Grindeks Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Grindeks Vigabatrin Product Portfolio
- 4.6.5 Grindeks Recent Developments
- 4.7 Endo International
- 4.7.1 Endo International Company Information
- 4.7.2 Endo International Business Overview
- 4.7.3 Endo International Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Endo International Vigabatrin Product Portfolio
- 4.7.5 Endo International Recent Developments
- 4.8 Dr. Fisher Farma
- 4.8.1 Dr. Fisher Farma Company Information
- 4.8.2 Dr. Fisher Farma Business Overview
- 4.8.3 Dr. Fisher Farma Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Dr. Fisher Farma Vigabatrin Product Portfolio
- 4.8.5 Dr. Fisher Farma Recent Developments
- 4.9 Cipla
- 4.9.1 Cipla Company Information
- 4.9.2 Cipla Business Overview
- 4.9.3 Cipla Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Cipla Vigabatrin Product Portfolio
- 4.9.5 Cipla Recent Developments
- 4.10 Benta Pharma Industries
- 4.10.1 Benta Pharma Industries Company Information
- 4.10.2 Benta Pharma Industries Business Overview
- 4.10.3 Benta Pharma Industries Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Benta Pharma Industries Vigabatrin Product Portfolio
- 4.10.5 Benta Pharma Industries Recent Developments
- 4.11 Amneal Pharma
- 4.11.1 Amneal Pharma Company Information
- 4.11.2 Amneal Pharma Business Overview
- 4.11.3 Amneal Pharma Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Amneal Pharma Vigabatrin Product Portfolio
- 4.11.5 Amneal Pharma Recent Developments
5 Global Vigabatrin Market Scenario by Region
- 5.1 Global Vigabatrin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Vigabatrin Sales by Region: 2021-2032
- 5.2.1 Global Vigabatrin Sales by Region: 2021-2026
- 5.2.2 Global Vigabatrin Sales by Region: 2027-2032
- 5.3 Global Vigabatrin Revenue by Region: 2021-2032
- 5.3.1 Global Vigabatrin Revenue by Region: 2021-2026
- 5.3.2 Global Vigabatrin Revenue by Region: 2027-2032
- 5.4 North America Vigabatrin Market Facts & Figures by Country
- 5.4.1 North America Vigabatrin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Vigabatrin Sales by Country (2021-2032)
- 5.4.3 North America Vigabatrin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Vigabatrin Market Facts & Figures by Country
- 5.5.1 Europe Vigabatrin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Vigabatrin Sales by Country (2021-2032)
- 5.5.3 Europe Vigabatrin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Vigabatrin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Vigabatrin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Vigabatrin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Vigabatrin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Vigabatrin Market Facts & Figures by Country
- 5.7.1 South America Vigabatrin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Vigabatrin Sales by Country (2021-2032)
- 5.7.3 South America Vigabatrin Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Vigabatrin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Vigabatrin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Vigabatrin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Vigabatrin Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Vigabatrin Sales by Type (2021-2032)
- 6.1.1 Global Vigabatrin Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Vigabatrin Sales Market Share by Type (2021-2032)
- 6.2 Global Vigabatrin Revenue by Type (2021-2032)
- 6.2.1 Global Vigabatrin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Vigabatrin Revenue Market Share by Type (2021-2032)
- 6.3 Global Vigabatrin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Vigabatrin Sales by Application (2021-2032)
- 7.1.1 Global Vigabatrin Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Vigabatrin Sales Market Share by Application (2021-2032)
- 7.2 Global Vigabatrin Revenue by Application (2021-2032)
- 7.2.1 Global Vigabatrin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Vigabatrin Revenue Market Share by Application (2021-2032)
- 7.3 Global Vigabatrin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Vigabatrin Value Chain Analysis
- 8.1.1 Vigabatrin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Vigabatrin Production Mode & Process
- 8.2 Vigabatrin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Vigabatrin Distributors
- 8.2.3 Vigabatrin Customers
9 Global Vigabatrin Analyzing Market Dynamics
- 9.1 Vigabatrin Industry Trends
- 9.2 Vigabatrin Industry Drivers
- 9.3 Vigabatrin Industry Opportunities and Challenges
- 9.4 Vigabatrin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst